300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Oil and Gas
Retail
Payments
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Recruiting
Web3
Medical
Theatre
Social
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Infrastructure
Music
Art
Real Estate
Sporting Goods
Beauty
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Fashion
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Paraguay
Moldova
Seychelles
Botswana
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Argentina
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Bangladesh
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Shangbay Capital, VC Fund

Shangbay Capital

VC Fund

Palo Alto, United States

Shangbay Capital is a VC fund in Palo Alto focused on Health Care and Medical Device. Best-in-class investments mainly in the U.S. medical devices technology, as well as biotech, and mobile healthcare sectors through early sta

Total investments:
52
Last investment:
Lead investor:
25%
Fund size:
$48M
Last fund:

Last updated:

Industries Shangbay Capital invests in

Health CareMedical DeviceMedicalBiotechnologyTherapeutics

Stages Shangbay Capital invests in

Series ASeries BSeries DSeries CSeed

Countries Shangbay Capital invests in

United StatesChinaCanada

Round sizes

Series A $5.1M–$25MSeries B $10M–$123M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$5.1M–$25M
Series B
$10M–$123M

Investment Focus

Industry

  • Health Care 34 (65%)
  • Medical Device 22 (42%)
  • Medical 20 (38%)
  • Biotechnology 16 (31%)
  • Therapeutics 7 (13%)
See all 26 industries →

Stage

  • Series A 19 (37%)
  • Series B 12 (23%)
  • Series D 5 (10%)
  • Series C 4 (8%)
  • Seed 2 (4%)
See all 9 stages →

Country

  • United States 37 (71%)
  • China 1 (2%)
  • Canada 1 (2%)

Team

NameTitleInvestmentsLinksEmail
Erik Engelson
Erik Engelson Venture Partner
Venture Partner Total investments: 1
Find email
William Dai
William Dai Founding Managing Partner
Founding Managing Partner Total investments: 18
Find email

Investments

CompanyDescriptionRoundLinks
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. $66M / Series D / Aug 18, 2026
Sound Health uses acoustic resonance to provide nasal relief. Its current product is an app that scans the face to map the bone structure and then a headband that plays music at personalized frequencies for 10 minutes. The headband is off the shelf and the sound levels are akin to wearing earpods. It envisions the headband to be over-the-counter(OTC) so it’s easily accessible to patients, whether prescribed by doctors or not. $12.3M / Series A / Jul 30, 2026
Sound Health & Wellness Center offers health benefits via a Taft-Hartley trust, including virtual care and case management. $12.3M / Series A / Jul 28, 2026
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. $52.5M / Series B / Apr 27, 2026
Petal Surgical is a healthcare platform that intends to make surgery accessible and incisionless. $10M / Series A / Oct 20, 2025
SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. $115M / Series D / Aug 11, 2025
Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular. Series B / Mar 25, 2025
Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. $27M / Series A / Dec 16, 2024
Inquis Medical is developing thrombectomy technology, enabling an efficient single-pass thrombectomy with minimal blood loss. $40M / Series B / Nov 04, 2024
Venova Medical develops vascular access systems for patients requiring renal replacement therapy. It addresses patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for intervention. The company was founded in 2018 and is headquartered in Los Gatos, California. $30M / Series B / Sep 04, 2024
See all 52 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Oil and Gas
Retail
Payments
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Venture Capital
Recruiting
Web3
Medical
Theatre
Social
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Infrastructure
Music
Art
Real Estate
Sporting Goods
Beauty
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Fashion
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Paraguay
Moldova
Seychelles
Botswana
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Argentina
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Ethiopia
Austria
Bangladesh
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Shangbay Capital invest in?

Shangbay Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 52 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Shangbay Capital's check size?

Shangbay Capital typically joins rounds of $5.1M–$25M at Series A and $10M–$123M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shangbay Capital participates in.

How do I contact Shangbay Capital?

Public channels for Shangbay Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Shangbay Capital?

The team at Shangbay Capital includes Erik Engelson (Venture Partner) and William Dai (Founding Managing Partner). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Shangbay Capital Shangbay Capital Find emails